Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.51 |
| ▸ | AURKA | O14965 | 7/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.51 |
| ▸ | TEK | Q02763 | 7/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.51 |
| ▸ | KDR | P35968 | 5/20 | 0.51 |
| ▸ | FLT4 | P35916 | 4/20 | 0.51 |
| ▸ | FBP1 | P09467 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25215929 | 0.92 | EGFR (0.53) | EGFRAURKAPDGFRBTEKAURKB | |
| SCHEMBL25220782 | 0.92 | EGFR (0.49) | EGFRAURKAPDGFRBTEKAURKB | |
| SCHEMBL25663596 | 0.91 | EGFR (0.47) | EGFRAURKAPDGFRBTEKAURKB | |
| SCHEMBL25246042 | 0.89 | EGFR (0.48) | EGFRAURKAPDGFRBTEKAURKB | |
| SCHEMBL26055503 | 0.87 | EGFR (0.52) | EGFRAURKAPDGFRBTEKAURKB | |
| SCHEMBL25215331 | 0.86 | EPHA2 (0.45) | EGFRAURKAPDGFRBTEKAURKB | |
| SCHEMBL28969396 | 0.86 | EGFR (0.46) | EGFRAURKAPDGFRBTEKAURKB | |
| SCHEMBL25662592 | 0.83 | EGFR (0.53) | EGFRAURKAPDGFRBTEKAURKB | |
| SCHEMBL26055146 | 0.83 | EGFR (0.66) | EGFRPDGFRBAURKBERBB2KDR | |
| SCHEMBL25207968 | 0.82 | EGFR (0.48) | EGFRERBB2KDRFBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271936-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271936-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | EGFR, WEE1, WEE2 | EGFR 1/4885AURKA 2179/4885PDGFRB 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.